Any scientific innovation needs to translate into a significant benefit. 
Peginesatide is noninferior to other erythropoiesis stimulating agents (ESAs) in 
terms of efficacy, and it shares the advantages of other long-acting ESAs: 
delayed administration frequency and no changes in dose needs according to the 
administration route. The molecular structure of peginesatide does not require 
the use of recombinant DNA technology during the manufacturing process, making 
its synthesis simpler and likely economically cheaper. During clinical 
development, its safety profile seemed to be safe, excepting the potential 
increase in the risk of safety end-point events in nondialysis CKD patients. 
However postmarketing serious hypersensitivity reactions have completely changed 
the scenario and urgently needs in-depth clarification. This promising drug 
seems to have prematurely finished its prospects.